---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-003038"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:38:37.996908+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Milestone closes $75M royalty sale to RTW for etripamil US net sales

## Summary
- Closed sale of royalty interest under Royalty Purchase Agreement with RTW Royalty I DAC.
- Received $75 million purchase price from funds managed by RTW.
- Royalty interest is on annual net product sales of etripamil in the United States.
- Previously disclosed on March 27, 2023; FDA approval of etripamil a condition.

## SEC filing metadata
- accession: 0001104659-26-003038
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/0001104659-26-003038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465926003038/tm262948d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-003038
- JSON: https://secwatch.observer/filing/0001104659-26-003038.json
- Plain text: https://secwatch.observer/filing/0001104659-26-003038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.